Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader
The widely followed growth investor keeps making moves.
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
View interactive chart, options flow, and AI analysis for BEAM on Zorveq Finance.
Open BEAM Chart & Analysis →